Rethinking Climate Change Metrics

Written by Dr. Matthew Wielicki

The discussion surrounding global temperature anomalies and their role in climate science has sparked considerable controversy. Critics of the use of global temperature anomalies, which I am one of, as a primary metric for representing climate change argue that this approach can be reductionist and misleading, presenting relatively mild warming in a way that appears more alarming than it actually is. This article will investigate the reasons behind these claims, examining the scientific, statistical, and communication aspects of global temperature anomalies.

Continue Reading 1 Comment

Chicago’s Legal Battle Against Big Oil

Written by Dr. Matthew Wielicki

The city of Chicago has filed a lawsuit against five major oil and gas companies, including BP, Chevron, ConocoPhillips, ExxonMobil, and Shell, as well as the American Petroleum Institute, alleging that these companies have engaged in climate deception by misleading consumers about the dangers of climate change associated with their products. The lawsuit claims that these companies have known about the harmful effects of their products on the climate for decades and have actively concealed this information from the public.

Continue Reading 4 Comments

The Little Ice Age Enigma

Written by Dr. Matthew Wielicki

The Earth’s climate is a coupled, nonlinear, and chaotic system, influenced by a multitude of factors beyond any single variable. While the current rise in global temperatures is a concern, it’s crucial to understand that climate history is full of changes in surface temperature with little change in GHG concentration. For example, the Little Ice Age (LIA), a period of regional cooling between the 16th and 19th centuries, offers a valuable case study for understanding the limitations of solely attributing global temperature variations to CO2 levels.

Continue Reading 16 Comments

Moderna’s Great Immunological Blunder

Written by Peter A. McCullough, MD, MPH

Many have asked me how Moderna, a dedicated mRNA company, could make such a bad product out of the gate as their first market entry? Much of the answer relates to a development blunder made by Moderna scientists dating back many years.

Continue Reading No Comments